Journal
DRUG DISCOVERY TODAY
Volume 27, Issue 4, Pages 939-945Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2021.11.027
Keywords
Biopharmaceutical R&D; Public sector; Private sector; Investment; Contribution
Categories
Funding
- European Federation of Pharmaceutical Industries and Associations (EFPIA)
Ask authors/readers for more resources
This article examines the contributions of the private and public sectors to the research and development of new medicines, emphasizing the complementary and interwoven nature of both sectors in biopharmaceutical R&D.
When examining the prices of new medicines, the question of how much the private and public sectors have contributed to their R&D is often raised. Contributions can be assessed in terms of the investment, authorship of publications, marketing authorizations and intellectual property rights associated with biopharmaceutical R&D. This review of the empirical evidence underlines the complementary and interwoven nature of the private and public sectors in supporting biopharmaceutical R&D. Both sectors invest in and contribute to biopharmaceutical R&D, with the public sector predominantly focusing on basic research and the private sector mainly targeting medicine discovery and development. Public sector investment generates additional private-sector investment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available